keyword
https://read.qxmd.com/read/38691317/persistence-and-adherence-to-pcsk9-inhibitor-monoclonal-antibodies-versus-ezetimibe-in-real-world-settings
#1
JOURNAL ARTICLE
Paul Muntner, Lama Ghazi, Jenna Jones, Nafeesa Dhalwani, Bharat Poudel, Ying Wen, Ligong Chen, Zhixin Wang, Vera Bittner, Bethany Kalich, Michael E Farkouh, Mark Woodward, Lisandro D Colantonio, Robert S Rosenson
INTRODUCTION: The cardiovascular disease risk reduction benefits of proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i mAb) and ezetimibe are dependent on remaining on treatment and being persistent and adherent. We estimated the percentage of patients on therapy, persistent and adherent at 182 and 365 days among US adults with health insurance who initiated a PCSK9i mAb (n = 16,588) or ezetimibe (n = 83,086) between July 2015 and December 2019...
April 30, 2024: Advances in Therapy
https://read.qxmd.com/read/38687079/-in-vitro-enhancement-of-zika-virus-infection-by-preexisting-west-nile-virus-antibodies-in-human-plasma-derived-immunoglobulins-revealed-after-p2-binding-site-specific-enrichment
#2
JOURNAL ARTICLE
Yong He, Lilin Zhong, Hailing Yan, Maria Luisa Virata, Lu Deng, Ashish K Mishra, Evi Struble, Dorothy Scott, Pei Zhang
Human immunoglobulin preparations contain a diverse range of polyclonal antibodies that reflect past immune responses against pathogens encountered by the blood donor population. In this study, we examined a panel of intravenous immunoglobulins (IGIVs) manufactured over the past two decades (1998-2020) for their capacity to neutralize or enhance Zika virus (ZIKV) infection in vitro . These IGIVs were selected specifically based on their production dates in relation to the occurrences of two flavivirus outbreaks in the U...
April 30, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38656211/vaccines-and-monoclonal-antibodies-new-tools-for-malaria-control
#3
REVIEW
Kazutoyo Miura, Yevel Flores-Garcia, Carole A Long, Fidel Zavala
SUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to develop new tools, such as vaccines and monoclonal antibodies (mAbs), to fight malaria...
April 24, 2024: Clinical Microbiology Reviews
https://read.qxmd.com/read/38630049/advancements-in-diabetic-kidney-disease-management-integrating-innovative-therapies-and-targeted-drug-development
#4
REVIEW
Shaarav Ghose, Matthew Satariano, Saichidroopi Korada, Thomas Cahill, Raghav Shah, Rupesh Raina
Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and affects approximately 40% of diabetic individuals. Cases of DKD continue to rise globally as the prevalence of diabetes mellitus increases, with an estimated 415 million people living with diabetes in 2015 and a projected 642 million by 2040. DKD is associated with significant morbidity and mortality, representing 34% and 36% of all chronic kidney disease deaths in men and women, respectively. Common co-morbidities including hypertension and ageing-related nephron loss further complicate disease diagnosis and progression...
April 17, 2024: American Journal of Physiology. Endocrinology and Metabolism
https://read.qxmd.com/read/38629975/comparing-pcsk9-monoclonal-antibody-treatment-strategies-following-myocardial-infarction-using-negative-control-outcomes-a-target-trial-emulation-study
#5
JOURNAL ARTICLE
Rosa Sloot, Alexander Breskin, Lisandro D Colantonio, Andrew G Allmon, Ying Yu, Swati Sakhuja, Ligong Chen, Paul Muntner, M Alan Brookhart, Nafeesa Dhalwani
BACKGROUND: Initiation of proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9 mAb) for lipid-lowering following myocardial infarction (MI) is likely affected by patients' prognostic factors, potentially leading to bias when comparing real-world treatment effects. METHODS: Using target-trial emulation, we assessed potential confounding when comparing two treatment strategies post-MI: initiation of PCSK9 mAb within 1 year and no initiation of PCSK9 mAb...
March 12, 2024: Epidemiology
https://read.qxmd.com/read/38614375/combination-immune-checkpoint-and-targeted-protein-kinase-inhibitors-for-the-treatment-of-renal-cell-carcinomas
#6
REVIEW
Robert Roskoski
Kidney cancers comprise about 3% of all new malignancies in the United States. Renal cell carcinomas (RCCs) are the most common type of renal malignancy making up about 85% of kidney cancer cases. Signs and symptoms of renal cell carcinomas can result from local tumor growth, paraneoplastic syndromes, or distant metastases. The classic triad of presentation with flank pain, hematuria, and a palpable abdominal mass occurs in fewer than 10% of patients. Most diagnoses result from incidental imaging findings (ultrasonography or abdominal CT imaging) performed for another reason...
April 11, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38566063/migraine-treatment-quo-vadis-real-world-data-study-2015-2022-in-spain
#7
JOURNAL ARTICLE
Patricia Pozo-Rosich, Mafalda Carmo, Alejandro Muñiz, Beatriz Armada, Carlota Moya-Alarcón, Julio Pascual
BACKGROUND: Migraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas. METHODS: Non-interventional, retrospective, cross-sectional cohort study conducted using an electronic medical records database covering visits to public healthcare providers for 3% of the Spanish population. Patients with a migraine diagnosis (ICD-9 346) between 01/2015 and 04/2022 were included, as well as their demographic and clinical characteristics, prescribed migraine treatments and the specialty of the prescribing physicians...
April 2, 2024: BMC Neurology
https://read.qxmd.com/read/38541039/long-term-perspectives-on-chronic-rhinosinusitis-with-nasal-polyps-evaluating-recurrence-rates-after-functional-endoscopic-sinus-surgery-in-the-biologics-era-a-5-year-follow-up-study
#8
JOURNAL ARTICLE
Carlo Cavaliere, Simonetta Masieri, Elona Begvarfaj, Antonella Loperfido, Silvia Baroncelli, Francesca Cascone, Andrea Ciofalo
INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease with multifactorial etiopathogenesis. This study investigated the recurrence rate and risk factors predicting recurrence in patients subjected to Functional Endoscopic Sinus Surgery (FESS) for CRSwNP. METHODS: Patients affected by CRSwNP who underwent FESS between January 2015 and March 2020 were enrolled. The recurrence rate and the influence of risk factors were assessed...
March 10, 2024: Journal of Personalized Medicine
https://read.qxmd.com/read/38415046/real-world-safety-and-effectiveness-of-secukinumab-in-adult-patients-with-moderate-to-severe-plaque-psoriasis-results-from-postmarketing-surveillance-in-korea
#9
JOURNAL ARTICLE
Byung Soo Kim, Dong Hyun Kim, Bong Seok Shin, Eun-So Lee, Seong Jin Jo, Chul Hwan Bang, Yeojun Yun, Yong Beom Choe
BACKGROUND: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015. OBJECTIVES: To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea. DESIGN: Multicenter, real-world, noninterventional study conducted over 6 years. METHODS: Adults with moderate to severe psoriasis were enrolled...
2024: Therapeutic Advances in Chronic Disease
https://read.qxmd.com/read/38398257/low-density-lipoprotein-cholesterol-lowering-drugs-a-narrative-review
#10
REVIEW
Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, Alberto Corsini
The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo identified an active compound (compactin) that inhibited cholesterol biosynthesis from the culture broth of blue-green mold ( Penicillium citrinum Pen-51). Since 1987, statins have represented the milestone for the treatment of atherosclerotic cardiovascular disease. A new therapy for the treatment of hypercholesterolemia since the discovery of statins is ezetimibe, the first and only agent inhibiting intestinal cholesterol absorption...
February 7, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38374890/association-of-androgen-receptor-and-tumour-infiltrating-lymphocytes-with-bone-recurrence-in-triple-negative-breast-cancer
#11
JOURNAL ARTICLE
Petra Ilenič, Ajda Herman, Erik Langerholc, Barbara Gazić, Boštjan Šeruga
BACKGROUND: As compared to endocrine responsive breast cancer bone is less frequent site of distant recurrence in triple-negative breast cancer (TNBC). A biomarker which predicts bone recurrence would allow a more personalized treatment approach with adjuvant bisphosphonates in TNBC. Here we hypothesised that tumour expression of androgen receptor (AR) is associated with bone recurrence in TNBC. MATERIALS AND METHODS: Patients with operable TNBC who were treated at the Institute of Oncology Ljubljana between 2005 and 2015 and developed distant recurrence were included into our study...
February 2024: Journal of Bone Oncology
https://read.qxmd.com/read/38371335/hemophagocytic-lymphohistiocytosis-is-associated-with-deficiency-and-closed-conformation-of-adamts-13
#12
JOURNAL ARTICLE
Amélie Launois, Sandrine Valade, Eric Mariotte, Lionel Galicier, Elie Azoulay, Elien Roose, Karen Vanhoorelbeke, Agnès Veyradier, Bérangère S Joly
BACKGROUND: A disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS-13) is the specific von Willebrand factor-cleaving protease and circulates in a closed and latent conformation due to a spacer/CUB1 domain interaction. ADAMTS-13 is allosterically activated after binding of its substrate or antibodies, inducing an open conformation. Recently, we suggested a potential role of plasmin (fibrinolysin) in hemostasis disorders reported in most patients with hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening condition related to a severe systemic inflammatory state...
January 2024: Research and Practice in Thrombosis and Haemostasis
https://read.qxmd.com/read/38349142/prior-dengue-virus-serotype-3-infection-modulates-subsequent-plasmablast-responses-to-zika-virus-infection-in-rhesus-macaques
#13
JOURNAL ARTICLE
Tulika Singh, Itzayana G Miller, Sravani Venkatayogi, Helen Webster, Holly J Heimsath, Josh A Eudailey, Dawn M Dudley, Amit Kumar, Riley J Mangan, Amelia Thein, Matthew T Aliota, Christina M Newman, Mariel S Mohns, Meghan E Breitbach, Madison Berry, Thomas C Friedrich, Kevin Wiehe, David H O'Connor, Sallie R Permar
Immunodominant and highly conserved flavivirus envelope proteins can trigger cross-reactive IgG antibodies against related flaviviruses, which shapes subsequent protection or disease severity. This study examined how prior dengue serotype 3 (DENV-3) infection affects subsequent Zika virus (ZIKV) plasmablast responses in rhesus macaques ( n = 4). We found that prior DENV-3 infection was not associated with diminished ZIKV-neutralizing antibodies or magnitude of plasmablast activation. Rather, characterization of 363 plasmablasts and their derivative 177 monoclonal antibody supernatants from acute ZIKV infection revealed that prior DENV-3 infection was associated with a differential isotype distribution toward IgG, lower somatic hypermutation, and lesser B cell receptor variable gene diversity as compared with repeat ZIKV challenge...
February 13, 2024: MBio
https://read.qxmd.com/read/38302221/elotuzumab-lenalidomide-bortezomib-dexamethasone-and-autologous-haematopoietic-stem-cell-transplantation-for-newly-diagnosed-multiple-myeloma-gmmg-hd6-results-from-a-randomised-phase-3-trial
#14
RANDOMIZED CONTROLLED TRIAL
Elias K Mai, Hartmut Goldschmid, Kaya Miah, Uta Bertsch, Britta Besemer, Mathias Hänel, Julia Krzykalla, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor W Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Christoph Mann, Niels Weinhold, Christof Scheid, Roland Schroers, Ivana von Metzler, Aneta Schieferdecker, Jörg Thomalla, Peter Reimer, Rolf Mahlberg, Ullrich Graeven, Stephan Kremers, Uwe M Martens, Christian Kunz, Manfred Hensel, Axel Benner, Andrea Seidel-Glätzer, Katja C Weisel, Marc S Raab, Hans J Salwender
BACKGROUND: The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma. METHODS: GMMG-HD6 was a phase 3, randomised trial conducted at 43 main trial sites and 26 associated trial sites throughout Germany. Adult patients (aged 18-70 years) with previously untreated, symptomatic multiple myeloma, and a WHO performance status of 0-3, with 3 being allowed only if caused by myeloma disease and not by comorbid conditions, were randomly assigned 1:1:1:1 to four treatment groups...
February 2024: Lancet Haematology
https://read.qxmd.com/read/38240489/mepolizumab-in-children-and-adolescents-with-severe-eosinophilic-asthma-not-eligible-for-omalizumab-a-single-center-experience
#15
JOURNAL ARTICLE
Y T Lim, T C Williams, R J Langley, E Weir
BACKGROUND: Mepolizumab is an anti-interleukin-5 monoclonal antibody shown to reduce asthma exacerbations in adults and adolescents with severe eosinophilic asthma. AIM: To assess the impact of mepolizumab on children and adolescents over 12 months by examining steroid usage, asthma-related hospitalizations, Asthma Control Test (ACT) scores, fractional exhaled nitric oxide concentration (FeNO), forced expiratory volume in 1 s (FEV1 ), mid expiratory flow (FEF25-75% ), and blood eosinophil count...
January 19, 2024: Journal of Asthma
https://read.qxmd.com/read/38216608/assessment-of-safety-profile-of-secukinumab-in-real-world-scenario-using-united-states-food-and-drug-administration-adverse-event-reporting-system-database
#16
JOURNAL ARTICLE
Vishnu Eshwar, Ashwin Kamath
Secukinumab is an anti-IL-17 monoclonal antibody approved for treating psoriasis and various arthritides. A comprehensive evaluation of its safety, especially in a real-world setting, is necessary. This study aimed to describe the adverse events (AE) associated with secukinumab use using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. FAERS data files containing AE reports from 2015 to 2021 were downloaded for data mining. Primary or secondary suspect medications indicated for psoriasis were identified and analyzed...
January 12, 2024: Scientific Reports
https://read.qxmd.com/read/38185077/predictors-and-prognostic-factors-influencing-outcomes-of-anti-cd20-monoclonal-antibodies-in-systemic-lupus-erythematosus-a-systematic-review-update
#17
REVIEW
Mia Rodziewicz, Claudia Mendoza-Pinto, Sarah Dyball, Pamela Munguía-Realpozo, Ben Parker, Ian N Bruce
BACKGROUND: Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but clinical outcomes are highly variable. We aimed to provide an update of a systematic review of predictive and prognostic factors of anti-CD20 MAb treatment in SLE. METHODS: A systematic literature search was undertaken to identify predictive and prognostic factors of clinical response following treatment with anti-CD20 therapies in SLE patients...
December 16, 2023: Seminars in Arthritis and Rheumatism
https://read.qxmd.com/read/38165296/genome-wide-association-studies-of-aria-from-the-aducanumab-phase-3-engage-and-emerge-studies
#18
JOURNAL ARTICLE
Stephanie J Loomis, Ryan Miller, Carmen Castrillo-Viguera, Kimberly Umans, Wenting Cheng, John O'Gorman, Richard Hughes, Samantha Budd Haeberlein, Christopher D Whelan
BACKGROUND AND OBJECTIVES: Amyloid-related imaging abnormalities (ARIA) were the most common adverse events reported in the phase 3 ENGAGE and EMERGE trials of aducanumab, an anti-amyloid monoclonal antibody. APOE ε4 carrier status has been shown to increase risk of ARIA in prior trials of aducanumab and other anti-amyloid therapies; however, the remainder of the human genome has not been evaluated for ARIA risk factors. Therefore, we sought to determine in a hypothesis-free manner whether genetic variants beyond APOE influence risk of ARIA in aducanumab-treated patients...
February 13, 2024: Neurology
https://read.qxmd.com/read/38150328/neutrophil-depletion-attenuates-antibody-mediated-rejection-in-a-renal-transplantation-mouse-model
#19
JOURNAL ARTICLE
Xingku Li, Yakun Zhao, Wenying Sun, Cong Zhang, Yadi Yu, Bo Du, AiShun Jin, Ye Liu
Antibody-mediated rejection (AMR) can cause graft failure following renal transplantation. Neutrophils play a key role in AMR progression, but the exact mechanism remains unclear. We investigated the effect of neutrophils on AMR in a mouse kidney transplantation model. The mice were divided into five groups: syngeneic transplantation (Syn), allograft transplantation (Allo), and three differently treated AMR groups. The AMR mouse model was established using skin grafts to pre-sensitize recipient mice. Based on the AMR model, Ly6G-specific monoclonal antibodies were administered to deplete neutrophils (NEUT-/- + AMR) and TACI-Fc was used to block B-cell-activating factor (BAFF)/a proliferation-inducing ligand (APRIL) signaling (TACI-Fc + AMR)...
December 27, 2023: Clinical and Experimental Immunology
https://read.qxmd.com/read/38130597/etiology-of-acute-lower-respiratory-illness-hospitalizations-among-infants-in-4-countries
#20
JOURNAL ARTICLE
John Kubale, Stephanie Kujawski, Irena Chen, Zhenke Wu, Ilham Abu Khader, Iris Hasibra, Brett Whitaker, Lionel Gresh, Artan Simaku, Eric A F Simões, Mahmoud Al-Gazo, Shannon Rogers, Susan I Gerber, Angel Balmaseda, Veronica L Tallo, Tareq M Al-Sanouri, Rachael Porter, Silvia Bino, Eduardo Azziz-Baumgartner, Meredith McMorrow, Danielle Hunt, Mark Thompson, Holly M Biggs, Aubree Gordon
BACKGROUND: Recent studies explored which pathogens drive the global burden of pneumonia hospitalizations among young children. However, the etiology of broader acute lower respiratory tract infections (ALRIs) remains unclear. METHODS: Using a multicountry study (Albania, Jordan, Nicaragua, and the Philippines) of hospitalized infants and non-ill community controls between 2015 and 2017, we assessed the prevalence and severity of viral infections and coinfections...
December 2023: Open Forum Infectious Diseases
keyword
keyword
65728
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.